The BIA campaigns for finance, tax and investment policies to support UK bioscience companies to start and scale up.
The Finance and Tax Advisory Committee (FTAC) leads the BIA’s policy development, drawing on the expertise and experience of the membership. Our strong links to the Treasury, HMRC and the Department for Business, Energy and Industrial Strategy (BEIS) ensure that the voice of the bioscience sector is heard at the highest levels. FTAC also provides finance and tax support for BIA members through events and guidance documents.
The UK is the European leader in bioscience investment and is in a strong position to close the gap on the leading life sciences clusters in Boston and San Francisco and achieve the BIA's vision of becoming the world's third-largest global biotech cluster. The BIA works with the investment community to raise the profile of UK bioscience. We publish quarterly and annual reports on the levels of investment in the sector which you can see below.
Biotech financing update: Mar 2022 - May 2022
The UK biotech sector has continued to attract investment despite global economic headwinds impacting all sectors. The new data on equity investment in the UK biotech and life sciences sector between March and May 2022 shows £450 million was raised.
Biotech financing update: Dec 2021 - Feb 2022
UK biotech companies continued to enjoy strong support from venture capital investors in the first quarter of 2022. According to new data published by the BioIndustry Association (BIA) and Clarivate, £453 million was raised, marking a record first quarter for private biotechs in the UK
UK Biotech Financing 2021
The latest UK Biotech Financing Report, published by the BioIndustry Association (BIA) and Clarivate, shows 2021 was the highest year on record for investments into UK biotech and life sciences companies. £4.5 billion was raised in public and private financings, £1.7 billion (60%) more than in 2020.
The science of success: UK Biotech Financing in 2020
UK biotech companies raised a record £2.8 billion in equity finance in 2020. The science of success: UK biotech in 2020, marks the best year for biotech investments ever recorded by the trade association and shows that since 2012 investment has increased by over 1000%.
UK Listed Biotech & Life Sciences: 2021 Year in Review
Biotech companies on London stock markets delivered market-beating returns in 2021 and attracted new investors looking for growth in a turbulent year, according to new analysis by the BIA and Radnor Capital Partners.
Over the course of 2021, the broad biotech index curated for returned +16% vs +14% for the FTSE All Share. Cell & Gene Therapy, Research Tools, Medical Devices and Small Molecule subsectors all returned over 20%.